Search alternatives:
point decrease » point increase (Expand Search)
mean decrease » a decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
point decrease » point increase (Expand Search)
mean decrease » a decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
-
1041
-
1042
Density plots of normalised consumer final power (PC) for the six example networks, shown over decreasing ratios of mean consumer to mean resource potential, .
Published 2020“…<p>Each plot shows the density for the normalised consumer final power at = 0.75, 0.5, and 0.25, from left to right, as the ratio decreases due to increased resource flow during the simulation. …”
-
1043
-
1044
Table_1_A point mutation in MC06g1112 encoding FLOWERING LOCUS T decreases the first flower node in bitter gourd (Momordica charantia L.).xlsx
Published 2023“…A point mutation (C277T) in MC06g1112, which results in a P93S amino acid mutation between parental lines, may be responsible for decreasing FFN in bitter gourd. …”
-
1045
-
1046
-
1047
-
1048
Prostate cancer incidentally discovered at the time of radical cystoprostatectomy does not decrease overall survival: Results from a large Chinese medical center
Published 2018“…Patients with incidental PCa had a significantly higher mean age (69.2 vs. 62.2 years, P=0.015). Among the 132 patients with PCa, prostate specific antigen (PSA) analysis was available in 76 patients (57.6%), with a median value of 1.06ng/mL, and 61 (80.3%) patients had a PSA value below 4ng/mL. …”
-
1049
-
1050
-
1051
-
1052
-
1053
-
1054
-
1055
-
1056
-
1057
-
1058
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
1059
-
1060